Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-31 00:40 | 2025-05-28 | ANTX | AN2 Therapeutics, Inc. | Leonard Braden Michael | 10% owner | SELL | $1.13 | 2,532,000 | $2,872,554 | 3,217,432 |
| 2025-05-30 21:40 | 2025-05-30 | CLNN | Clene Inc. | General Resonance LLC | 10% owner | SELL | $2.80 | 410 | $1,148 | 709,192 |
| 2025-05-31 02:00 | 2025-05-28 | CYRX | Cryoport, Inc. | Hariri Robert J | Director | SELL | $6.10 | 12,500 | $76,250 | 8,061 |
| 2025-05-30 23:30 | 2025-05-29 | UTHR | UNITED THERAPEUTICS Corp | MAHON PAUL A | Officer | OPT+S | $316.07 | 11,000 | $3,476,766 | 36,781 |
| 2025-05-29 23:17 | 2025-05-28 | ANTX | AN2 Therapeutics, Inc. | FitzPatrick Margaret M | Director | BUY | $1.18 | 8,610 | $10,133 | 8,610 |
| 2025-05-30 03:25 | 2025-05-28 | ARQT | Arcutis Biotherapeutics Inc. | Matsuda Masaru | Officer | SELL | $13.78 | 1,800 | $24,807 | 202,599 |
| 2025-05-30 04:53 | 2025-05-27 | LTRN | Lantern Pharma Inc. | Kreis Leslie W. | 10% owner | SELL | $2.99 | 56,237 | $168,419 | 125,332 |
| 2025-05-30 04:55 | 2025-05-27 | LTRN | Lantern Pharma Inc. | Fletcher Aaron G.L. | 10% owner | SELL | $2.99 | 56,237 | $168,419 | 125,332 |
| 2025-05-30 00:38 | 2025-05-27 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $16.18 | 3,250 | $52,593 | 23,000 |
| 2025-05-30 02:00 | 2025-05-27 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Director | SELL | $104.45 | 7,500 | $783,375 | 46,637 |
| 2025-05-29 22:58 | 2025-05-29 | CLNN | Clene Inc. | General Resonance LLC | 10% owner | SELL | $2.73 | 410 | $1,119 | 709,602 |
| 2025-05-29 23:01 | 2025-05-27 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $10.23 | 2,558 | $26,179 | 2,806,084 |
| 2025-05-29 03:41 | 2025-05-23 | VREO | Vireo Growth Inc. | Chicago Atlantic Opportunity Portfolio, LP | 10% owner | BUY | $0.38 | 64,000 | $24,512 | 32,653,668 |
| 2025-05-29 04:52 | 2025-05-27 | AXSM | Axsome Therapeutics, Inc. | Jacobson Mark L. | Officer | OPT+S | $104.07 | 40,673 | $4,232,636 | 5,783 |
| 2025-05-29 00:25 | 2025-05-23 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $27.24 | 86,270 | $2,349,978 | 96,674 |
| 2025-05-28 23:30 | 2025-05-27 | SILO | Silo Pharma, Inc. | Weisblum Eric | Director, Officer | BUY | $0.43 | 10,000 | $4,329 | 197,932 |
| 2025-05-28 23:08 | 2025-05-23 | EBS | Emergent BioSolutions Inc. | Katkin Keith | Director | SELL | $6.30 | 7,844 | $49,417 | 86,431 |
| 2025-05-28 21:05 | 2025-05-28 | CLNN | Clene Inc. | General Resonance LLC | 10% owner | SELL | $2.60 | 420 | $1,090 | 710,012 |
| 2025-05-29 03:06 | 2025-05-23 | LFCR | LIFECORE BIOMEDICAL, INC. DE | English Aron R. | 10% owner | SELL | $6.59 | 1,386,060 | $9,132,472 | 264,180 |
| 2025-05-28 00:56 | 2025-05-27 | FBLG | FibroBiologics, Inc. | Khoja Hamid | Officer | BUY | $0.84 | 20,000 | $16,800 | 31,250 |
| 2025-05-27 23:35 | 2025-05-22 | IBO | IMPACT BIOMEDICAL INC. | DSS, INC. | 10% owner | SELL | $0.55 | 161,000 | $88,003 | 0 |
| 2025-05-28 01:52 | 2025-05-22 | LGVN | Longeveron Inc. | Soffer Rock | Director | SELL | $1.32 | 2,000 | $2,640 | 230,034 |
| 2025-05-27 23:13 | 2025-05-27 | LLY | ELI LILLY & Co | Zakrowski Donald A | Officer | SELL | $716.41 | 1,000 | $716,410 | 4,840 |
| 2025-05-28 01:31 | 2025-05-27 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | OPT+S | $12.82 | 10,000 | $128,225 | 122,279 |
| 2025-05-28 00:42 | 2025-05-23 | OCUL | OCULAR THERAPEUTIX, INC | Nayak Sanjay | Officer | SELL | $7.17 | 1,862 | $13,351 | 281,623 |
| 2025-05-28 00:40 | 2025-05-23 | OCUL | OCULAR THERAPEUTIX, INC | Kaiser Peter | Officer | SELL | $7.17 | 2,974 | $21,324 | 207,104 |
| 2025-05-28 00:39 | 2025-05-23 | OCUL | OCULAR THERAPEUTIX, INC | Heier Jeffrey S. | Officer | SELL | $7.18 | 3,024 | $21,712 | 262,974 |
| 2025-05-28 00:37 | 2025-05-23 | OCUL | OCULAR THERAPEUTIX, INC | Dugel Pravin | Director, Officer | SELL | $7.18 | 21,219 | $152,352 | 3,499,099 |
| 2025-05-28 02:57 | 2025-05-27 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Director | SELL | $6.38 | 2,000 | $12,760 | 90,435 |
| 2025-05-27 23:06 | 2025-05-23 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $11.31 | 2,146 | $24,272 | 113,026 |
| 2025-05-27 23:05 | 2025-05-23 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $11.31 | 1,926 | $21,782 | 98,189 |
| 2025-05-27 22:29 | 2025-05-27 | CLNN | Clene Inc. | General Resonance LLC | 10% owner | SELL | $2.45 | 420 | $1,029 | 710,432 |
| 2025-05-27 23:02 | 2025-05-22 | GYRE | GYRE THERAPEUTICS, INC. | Ma Songjiang | Director, Officer | SELL | $10.91 | 2,182 | $23,804 | 2,808,642 |
| 2025-05-24 04:30 | 2025-05-21 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | CHEN THOMAS C | Director, Officer, 10% owner | BUY | $7.32 | 5,468 | $40,002 | 551,668 |
| 2025-05-24 04:28 | 2025-05-22 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | GARNETT KEITHLY | Officer | BUY | $7.29 | 675 | $4,921 | 240,900 |
| 2025-05-24 00:30 | 2025-05-22 | AKRO | Akero Therapeutics, Inc. | Lamy Patrick | Officer | OPT+S | $50.00 | 4,000 | $200,000 | 33,492 |
| 2025-05-24 04:31 | 2025-05-23 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | Heshmatpour Amir F | Director, Officer | BUY | $7.39 | 2,000 | $14,785 | 1,762,000 |
| 2025-05-23 23:46 | 2025-05-21 | AEON | Aeon Biopharma Inc. | FISCHER JOST | Director | BUY | $0.49 | 60,000 | $29,250 | 266,785 |
| 2025-05-23 23:04 | 2025-05-21 | ARQT | Arcutis Biotherapeutics Inc. | Heron Patrick J | Director | BUY | $13.66 | 5,040 | $68,821 | 22,534 |
| 2025-05-23 23:26 | 2025-05-22 | KALV | KalVista Pharmaceuticals, Inc. | Audhya Paul K. | Officer | OPT+S | $11.88 | 2,689 | $31,933 | 110,172 |
| 2025-05-23 23:25 | 2025-05-22 | KALV | KalVista Pharmaceuticals, Inc. | Yea Christopher | Officer | OPT+S | $11.88 | 2,317 | $27,516 | 96,990 |
| 2025-05-23 23:24 | 2025-05-22 | KALV | KalVista Pharmaceuticals, Inc. | Palleiko Benjamin L | Director, Officer | OPT+S | $11.88 | 9,999 | $118,743 | 306,618 |
| 2025-05-23 23:06 | 2025-05-21 | PHAT | Phathom Pharmaceuticals, Inc. | Topper James N | Director | BUY | $3.86 | 3,780 | $14,609 | 59,403 |
| 2025-05-23 16:04 | 2025-05-21 | PHIO | Phio Pharmaceuticals Corp. | Bitterman Robert J | Director, Officer | BUY | $1.77 | 4,200 | $7,446 | 23,649 |
| 2025-05-23 00:55 | 2025-05-19 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | GARNETT KEITHLY | Officer | BUY | $7.23 | 135 | $976 | 240,225 |
| 2025-05-23 00:54 | 2025-05-13 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | GARNETT KEITHLY | Officer | BUY | $7.01 | 90 | $631 | 240,090 |
| 2025-05-23 01:31 | 2025-05-20 | IRON | Disc Medicine, Inc. | Savage William Jacob | Officer | SELL | $50.04 | 6,677 | $334,128 | 59,721 |
| 2025-05-23 00:00 | 2025-05-20 | SPRY | ARS Pharmaceuticals, Inc. | Scott Kathleen D. | Officer | OPT+S | $14.10 | 50,000 | $705,165 | 7,424 |
| 2025-05-23 04:00 | 2025-05-20 | ROIV | Roivant Sciences Ltd. | Venker Eric | Officer | OPT+S | $10.95 | 100,000 | $1,095,000 | 1,077,197 |
| 2025-05-22 23:38 | 2025-05-20 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $27.02 | 2,349 | $63,470 | 96,674 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.